ReviewDiscover oncology2025
From lab to life: technological innovations in transforming cancer metastasis detection and therapy.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Poly (lactic-co-glycolic acid) nanoplatforms for triple-negative breast cancer: current progress, advances, and future outlook.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Review
- Modeling and targeting the hostile physicochemical niche in bone metastasis: from experimental platforms to niche-directed therapy.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Cancer metastasis remains the leading cause of cancer-related mortality and represents a major therapeutic bottleneck, primarily due to the limited availability of effective, targeted treatment strategies. While key oncogenic drivers such as HER2, EGFR, PIK3CA, KRAS, and BRAF activate critical pathways like PI3K/AKT and MAPK/ERK, promoting tumor proliferation and migration and metastasis. In addition, metastasis is also influenced by environmental factors, microbiomes, and genomic alterations. This complex interplay underscores the urgent need for comprehensive mechanistic insights into metastatic progression, alongside the development of innovative translational platforms. This review explores the external contributors to metastasis, including air and water pollution, chemical exposures, and microbiome dysbiosis, which impact tumor progression and immune evasion. It also discusses the roles of viral infections, organotropism, and genomic regulation in driving metastasis heterogeneity. To address these challenges, a novel integrative framework has been proposed that connects environmental modulators, tumor-associated microbiota, and oncogenic genomic alterations with cutting-edge methodologies such as 3D bioprinting, microphysiological systems, liquid biopsy, and advanced in vitro and in vivo models. High-resolution imaging and AI-driven multi-omics integration further enhance the precision of these approaches. By transcending traditional and reductionist, tumor-centric paradigms, this framework advocates for a systems-level, translational framework that bridges molecular insights with clinical applicability. Ultimately, this strategy seeks to resolve persistent therapeutic challenges in metastatic cancer management through interdisciplinary collaboration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.